Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hanmi, Spectrum Look For Differentiation As Poziotinib Progresses

This article was originally published in PharmAsia News

Executive Summary

South Korea's Hanmi Pharmaceutical and its global partner Spectrum Pharmaceuticals are moving closer to the commercialization of the oral pan-HER inhibitor poziotinib in the US with the submission by the US biotech of a Phase II breast cancer protocol to the FDA as part of an IND application. But the partners are having to fine-tune their development strategy given what is a crowded sector.

Advertisement

Related Content

Spectrum Failed To Heed FDA Advice On Apaziquone, And Is Paying The Price

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC088541

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel